We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGBS
151
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.52M 0.06%
315,723
-57,727
-15% -$259K
KYNB
152
Kyntra Bio
KYNB
$27.4M
$1.5M 0.06%
2,907
-984
-25% -$464K
VTGN icon
153
VistaGen Therapeutics
VTGN
$9.98M
$1.45M 0.05%
11,637
-9,140
-44% -$993K
ONCS
154
DELISTED
OncoSec Medical Incorporated
ONCS
$1.43M 0.05%
3,791
+1,027
+37% +$393K
RXDX
155
DELISTED
Ignyta, Inc.
RXDX
$1.42M 0.05%
225,900
+900
+0.4% +$5.23K
XYLO
156
DELISTED
Xylo Technologies
XYLO
$1.37M 0.05%
+652
New +$1.6M
RCKT icon
157
Rocket Pharmaceuticals
RCKT
$343M
$1.36M 0.05%
36,001
+9,387
+35% +$295K
ACHN
158
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$1.36M 0.05%
1,681
+681
+68% +$5.79K
ENLV icon
159
Enlivex Ltd
ENLV
$37.9M
$1.36M 0.05%
1,307
-77
-6% -$78.2K
ONSIZ
160
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$1.33M 0.05%
926,651
+489,728
+112% +$357K
SIOX
161
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.3M 0.05%
11,639
-12,111
-51% -$1.45M
TXMD icon
162
CALL
TherapeuticsMD
TXMD
$23.8M
$1.3M 0.05%
38
+15
+65% +$5.48K
SRRA
163
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.25M 0.05%
17,193
+2,443
+17% +$189K
SAGE
164
PUT
DELISTED
Sage Therapeutics
SAGE
$1.22M 0.05%
265
-3,231
-92% -$132K
ENDP
165
DELISTED
Endo International plc
ENDP
$1.19M 0.04%
59,237
-824
-1% -$16.4K
ARCT icon
166
CALL
Arcturus Therapeutics
ARCT
$165M
$1.19M 0.04%
689
+51
+8% +$1.65K
CAPR icon
167
Capricor Therapeutics
CAPR
$1.18M 0.04%
35,744
+17,536
+96% +$659K
ACOR
168
PUT
DELISTED
Acorda Therapeutics
ACOR
$1.18M 0.04%
5
+4
+400% +$11.9K
MBAI
169
Check-Cap
MBAI
$8.04M
$1.16M 0.04%
+2,440
New +$1.05M
BCRX icon
170
CALL
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.14M 0.04%
+2,584
New +$10.3K
ONTXW
171
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$1.12M 0.04%
+725,434
New +$768K
MNKD icon
172
MannKind Corp
MNKD
$1.19B
$1.11M 0.04%
+357,074
New +$1.58M
IMNN icon
173
Imunon
IMNN
$6.47M
$1.09M 0.04%
327
-228
-41% -$779K
LXRX icon
174
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.08M 0.04%
600
-379
-39% -$6.1K
RIBT
175
DELISTED
RiceBran Technologies
RIBT
$1.07M 0.04%
79,444
+896
+1% +$13.2K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.